

Peroxisomal monoubiquitinated PEX5 interacts with the AAA ATPases PEX1 and PEX6 and is unfolded during its dislocation into the cytosol

Ana G. Pedrosa^{1,2,3,#}, Tânia Francisco^{1,2,#}, Diana Bicho^{1,2}, Ana F. Dias^{1,2,3}, Aurora Barros-Barbosa^{1,2}, Vera Hagemann⁴, Gabriele Dodt⁴, Tony A. Rodrigues^{1,2,3}, Jorge E. Azevedo^{1,2,3,*}

From the ¹Instituto de Investigação e Inovação em Saúde (i3S), ²Instituto de Biologia Molecular e Celular (IBMC) and ³Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal; ⁴Interfakultäres Institut für Biochemie, Universität Tübingen, Hoppe Seyler Str.4, 72076 Tübingen, Germany

Running title: Ub-PEX5 is a substrate of the PEX1.PEX6 complex

These authors contributed equally to this work.

* Corresponding author: Jorge E. Azevedo, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal; tel: +351220408800; Email: jazevedo@ibmc.up.pt

Keywords: ATPases associated with diverse cellular activities (AAA); Peroxisome; PEX5; PEX1; PEX6; ubiquitin; protein sorting; protein translocation

ABSTRACT

PEX1 and PEX6 are two members of the ATPases Associated with diverse cellular Activities (AAA) family and the core components of the receptor export module (REM) of the peroxisomal matrix protein import machinery. Their role is to extract monoubiquitinated PEX5, the peroxisomal protein shuttling receptor, from the peroxisomal membrane docking/translocation module (DTM), so that a new cycle of protein transportation can start. Recent data have shown that PEX1 and PEX6 form a heterohexameric complex which unfolds substrates by processive threading. However, whether the natural substrate of the PEX1.PEX6 complex is monoubiquitinated PEX5 (Ub-PEX5) itself or some Ub-PEX5-interacting component(s) of the DTM remains unknown. In this work, we used an established cell-free *in vitro* system coupled with photoaffinity crosslinking and protein PEGylation assays to address this problem. We provide evidence suggesting that DTM-embedded Ub-PEX5 interacts directly with both PEX1 and PEX6 through its ubiquitin moiety and that the PEX5 polypeptide chain is globally unfolded during the ATP-dependent extraction event. These findings strongly suggest that DTM-embedded Ub-PEX5 is a bona fide substrate of the PEX1.PEX6 complex.

INTRODUCTION

Peroxisomes are cytoplasmic organelles delimited by a single membrane found in almost all eukaryotes (1). In mammals, they harbor a set of approximately 100 different proteins and are involved in several metabolic pathways such as β -oxidation of fatty acids, synthesis of plasmalogens and bile acids, and detoxification of glyoxylate (2–6). Despite their simplicity, peroxisomes play important roles in human health and development, as demonstrated by a group of inherited metabolic disorders in which peroxisomes are partially or even completely defective, the peroxisomal biogenesis disorders (7). These diseases are caused by mutations in genes encoding proteins mechanistically involved in several aspects of peroxisome biogenesis – the so-called peroxins or PEX proteins (6–8). In mammals 16 peroxins are presently known, 10 of which are components of the machinery that sorts newly synthesized proteins to the organelle matrix (reviewed in (9)).

Proteins destined to the peroxisomal matrix are synthesized in the cytosol and transported to the organelle membrane by PEX5, the peroxisomal matrix protein shuttling receptor (10–20). There, cargo-loaded PEX5 interacts with the docking/translocation module (DTM), a multisubunit transmembrane complex comprising the core components PEX2, PEX10, PEX12, PEX13 and PEX14 (21, 22). This

interaction culminates with the insertion of PEX5 into the DTM with the concomitant translocation and release of the cargo protein into the organelle matrix (23–26). No ATP hydrolysis or a membrane potential is needed for these steps; the driving force for the complete cargo transport process resides in the strong protein-protein interactions that are established between PEX5 and DTM components (23, 25, 27).

After releasing its cargo, PEX5 has to be extracted from the DTM so that a new protein transport cycle can be initiated. Recycling of PEX5 involves three steps. First, DTM-embedded PEX5 is monoubiquitinated at a conserved cysteine residue (Cys11 in the human protein) (28, 29). Then, monoubiquitinated PEX5 (Ub-PEX5) is extracted into the cytosol in an ATP hydrolysis-dependent manner by the so-called receptor export module (REM) (27, 30, 31). This is a protein complex comprising PEX1 and PEX6, two members of the AAA ATPases family, plus a poorly conserved peroxisomal membrane protein (PEX26 in mammals, APEM9 in plants, or PEX15 in yeasts/fungi) which anchors the ATPases to the organelle membrane (32–34). Finally, Ub-PEX5 is deubiquitinated in the cytosol probably by a combination of enzymatic and non-enzymatic events (35–37).

Although the general properties of the PEX5-mediated protein import pathway are known, the mechanistic details of each of its steps remain mostly unclear. In this work, we focused on the mechanism used by the REM to extract Ub-PEX5 from the DTM.

An abundance of structural/functional data was recently reported for the yeast REM. These include electron microscopy structures of the PEX1.PEX6 complex, an X-ray structure of the cytosolic domain of PEX15, and the structure of a trimeric complex containing these three proteins (reviewed in (38); (39–42)). These studies revealed that PEX1 and PEX6 assemble into a ring-shaped heterohexameric complex, best described as a trimer of PEX1.PEX6 heterodimers, displaying a relatively large pore at its center. These data, together with mutational analyses of PEX1 and PEX6 showing that the conserved hydrophobic residues of the so-called pore loops are important for PEX1.PEX6 function, might suggest that the PEX1.PEX6 complex uses its pore to handle substrates (39, 40, 42). Robust data showing that the PEX1.PEX6 complex indeed unfolds

substrates in a pore loop-dependent manner using a processive threading mechanism were reported very recently (42). Surprisingly, the unfolding/threading activity of the PEX1.PEX6 complex was detected using a soluble fragment of PEX15 as substrate, but whether or not PEX15 is a natural substrate for these ATPases remains unknown, as thoroughly discussed by the authors of that work ((42); see also Discussion).

Here, we asked whether or not DTM-embedded Ub-PEX5 displays properties of a bona fide REM substrate. Our data shows that DTM-embedded Ub-PEX5 interacts directly with PEX1.PEX6 and is globally unfolded during the ATP-dependent extraction step. This suggests that Ub-PEX5 is indeed a natural substrate of the REM.

RESULTS

The results reported below were obtained with a cell-free *in vitro* system that recapitulates all the steps of the PEX5-mediated protein import pathway. This experimental system was thoroughly described recently (43) but a brief explanation is provided here for clarity. The core of the system is a rat liver post-nuclear supernatant (PNS; the source of peroxisomes and cytosolic proteins), which is incubated with an *in vitro* synthesized radiolabeled PEX5 protein under appropriate conditions. During this incubation, a fraction of the radiolabeled PEX5 protein becomes inserted into the peroxisomal DTM, where it is subsequently monoubiquitinated at cysteine 11, and rapidly exported into the cytosol by the REM in an ATP-dependent manner. A number of strategies can be used to block this pathway (43). For instance, AMP-PNP and ATP γ S, two ATP analogs used in this work, are excellent substrates for the ubiquitin-conjugating cascade (36, 44) but potent inhibitors of the REM (36). Thus, *in vitro* assays containing one of these nucleotides will reveal an accumulation of Ub-PEX5 at the peroxisomal DTM, particularly so if the PNS was previously “primed”, *i.e.*, pre-incubated with a small amount of ATP to release endogenous PEX5 from the DTMs (25). Two types of *in vitro* assays are used here: the so-called single-step and the two-step import/export assays. The first involves a single incubation of the reaction mixture. If such an assay is

performed in the presence of ATP then all the steps of the pathway will occur, *i.e.*, radiolabeled PEX5 will continuously interact with the DTM, where it is monoubiquitinated and subsequently exported into the soluble phase of the assay. Thus, if at the end of the incubation period the PNS is centrifuged to separate organelles from soluble proteins, most monoubiquitinated PEX5 will be detected in the soluble fraction. In the two-step import/export assay, a radiolabeled PEX5 protein is first accumulated at the DTM in the presence of AMP-PNP or ATP γ S (the first step of the assay); the organelles are then isolated by centrifugation, resuspended and incubated in buffer containing ATP (the second step), to allow export of the Ub-PEX5 protein into the soluble phase of the assay (36). The two-step assay is particularly suited to characterize events downstream of the monoubiquitination step. For practical reasons related to the lability of the thiol ester bond linking ubiquitin to cysteine 11 of PEX5 (29), all the PEX5 proteins used in this work contain instead a lysine at position 11. These C11K mutants are fully functional both *in vitro* and *in vivo* (35), but the corresponding monoubiquitinated forms are much more resistant upon SDS-PAGE, which can be performed under reducing conditions. Also, many of the experiments described here were performed with a truncated protein comprising amino acid residues 1-324 of PEX5 and derivatives of it. This protein lacks the globular tetratricopeptide-repeat domain of PEX5 and thus is unable to bind efficiently PTS1-containing proteins. However, all the other functions of the receptor are preserved in this C-terminal truncated species (45). Finally, two read-outs are possible in these assays. One, a protease-protection assay, explores the fact that PEX5, or truncated versions of it, are extremely sensitive to proteases, such as proteinase K, unless they are inserted into the DTM. In the other, no protease-treatment is performed - one just monitors the distribution of monoubiquitinated PEX5 species between the organelle and soluble fractions of the assay by SDS-PAGE/autoradiography. It is important to note that in the latter case, large amounts of non-ubiquitinated PEX5 species will be detected in the organelle pellets. Although a fraction of this

material represents non-ubiquitinated PEX5 specifically interacting with the DTM, the majority may represent PEX5 protein non-specifically adsorbed to the organelles, some of which may even appear in the supernatant fraction of a two-step assay. Thus, no conclusions are drawn from the behavior of these non-ubiquitinated PEX5 species.

Neither the N- nor the C-terminus of DTM-embedded Ub-PEX5 is important for the export step.

Many members of the AAA family of mechanoenzymes explore the presence of extended N- or C-termini in their substrates to unfold or pull them out of protein complexes (46, 47). For instance, katanin, a member of the AAA microtubule-severing family, extracts tubulin from microtubules by grabbing and pulling its disordered C-terminal tail (48, 49). As a first step to understand how Ub-PEX5 is dislocated from the DTM, we asked whether a similar mechanism might be valid for the peroxisomal REM.

We know from previous work that no particular C-terminal domain of PEX5 is important for the dislocation process because truncated proteins comprising amino acid residues 1-324, 1-197 or 1-125 of PEX5 are all functional in the dislocation step (45, 50). Also, we have recently shown that a PEX5 protein possessing an enhanced GFP (EGFP) moiety at its C-terminus is still a substrate for the dislocation machinery (51). Indeed, although that PEX5-EGFP fusion protein was not efficiently released from the DTM, protease protection assays revealed that most of the protein that accumulated at the peroxisome in the presence of ATP was already largely exposed into the cytosol, indicating that the C-terminal EGFP moiety interferes with the dislocation machinery only at late stages of the extraction process. Additional data indicating that the presence of an unrelated protein domain at the C-terminus of a PEX5 protein does not interfere with the dislocation process were obtained when a 35 S-labeled fusion protein comprising the first 324 amino acid residues of PEX5 fused to ubiquitin lacking its last two glycine residues (PEX5(1-324;C11K)-Ub(1-74); see Fig. 1 for a schematic representation of the PEX5 proteins used in this work) was used in a cell-free *in vitro* two-step import/export assay (36). Similarly to 35 S-labeled PEX5(1-

324;C11K), used here as a positive control (Fig. 2A, two lower panels; (36)), monoubiquitinated PEX5(1-324;C11K)-Ub(1-74) was efficiently dislocated into the soluble phase of the reaction when ATP (but not AMP-PNP) was used in the second step of the assay. Identical results were obtained with a similar PEX5 protein in which mouse dehydrofolate reductase (DHFR) was substituted for Ub(1-74) (see later). Thus, we next focused on the N-terminus of PEX5.

DTM-embedded PEX5 exposes a 2 to 3-kDa domain from its N-terminus into the cytosol (45, 52). This small domain comprises cysteine 11, the residue that has to be monoubiquitinated so that PEX5 can be extracted by the REM. Thus, the REM might extract Ub-PEX5 from the DTM by interacting with its first 10 amino acid residues. To test this, we produced a protein comprising amino acid residues 10 to 324 of PEX5 (PEX5(10-324;C11K)) and assessed the capacity of this protein to enter the DTM, be monoubiquitinated and extracted back into the cytosol using a single-step *in vitro* import/export assay. As shown in Fig. 2B, the amounts of monoubiquitinated PEX5(10-324;C11K) and PEX5(1-324;C11K) detected in the supernatants of the reactions made in the presence of ATP are similar. Taken together, these data suggest that if the REM recognizes DTM-embedded Ub-PEX5 through a direct interaction, this interaction does not involve a free disordered N- or C-terminal end on PEX5.

DTM-embedded Ub-PEX5 can be crosslinked to both PEX1 and PEX6 through its ubiquitin moiety.

DTM-embedded PEX5 can only be exported back into the cytosol after monoubiquitination at its Cys11 residue. Thus, in principle, the ubiquitin moiety attached to PEX5 might interact with the REM. However, experimental evidence supporting this possibility is still lacking. We note that there are some data suggesting that both non-ubiquitinated and monoubiquitinated PEX5 interact with AWP1, a cytosolic protein reported to bind PEX6 and seemingly necessary for the export step (53). However, AWP1 does not interact with the PEX1.PEX6 protein complex, the active form of the REM (53), and thus the exact role of AWP1 in the dislocation process remains undefined.

Aiming at better understanding the role of ubiquitin in PEX5 dislocation, we used a photocrosslinking approach (54, 55) to identify

the molecular neighbors of the ubiquitin moiety in the DTM-embedded Ub-PEX5 species. For this purpose four recombinant ubiquitin molecules, each harboring a photocrosslinking *p*-benzoyl-L-phenylalanine (*p*Bpa) residue at a different position (see Fig. 3A), were produced and used in cell-free *in vitro* assays programmed with ³⁵S-labeled PEX5(1-324;C11K) and performed in the presence of AMP-PNP. Organelle suspensions from these assays were then exposed to UV light, to elicit photocrosslinking, and subjected to SDS-PAGE/autoradiography analyses. The results of these experiments are shown in Fig. 3B. In all cases, the most prominent UV-induced radiolabeled bands were detected in the high molecular weight region of the SDS-gel, suggesting that Ub-PEX5(1-324;C11K) (molecular mass of 45 kDa) was crosslinked to some large proteins, probably PEX1 and/or PEX6 (note that PEX1 and PEX6 are by far the two largest components of the peroxisomal protein import machinery displaying molecular masses of 141 and 104 kDa, respectively; (56–58)).

To determine whether or not PEX1 and/or PEX6 are components of these crosslinked products, photocrosslinked organelles were solubilized in a denaturing SDS-containing buffer and subjected to immunoprecipitation using either control IgGs or antibodies directed to PEX1 or PEX6. As shown in Fig. 3C, we were able to immunoprecipitate significant amounts of PEX1 without precipitating also PEX6, and vice-versa (see the two lower panels), showing that protein complexes were efficiently disrupted by the solubilization procedure. Autoradiography analyses of immunoprecipitates revealed that the main photocrosslinked products obtained with Ub(A28*p*Bpa), Ub(D39*p*Bpa), and Ub(Q49*p*Bpa) comprise PEX6, whereas those obtained with Ub(Q62*p*Bpa) contain PEX1. Clearly, the ubiquitin moiety of DTM-embedded Ub-PEX5(1-324;C11K) is very close to both PEX1 and PEX6, probably not more than a few Angstroms apart (59). Furthermore, the fact that Ub(Q62*p*Bpa)-PEX5(1-324;C11K) reacts mainly with PEX1 whereas PEX5(1-324;C11K) modified with any of the other three *p*Bpa-modified ubiquitins reacts mainly with PEX6, suggests that the ubiquitin moiety in the DTM-embedded Ub-PEX5 species does not wobble freely, but rather that it exists in a movement-restricted location, *i.e.*, in a binding site.

Extraction of Ub-PEX5 from the DTM involves/requires global unfolding of its polypeptide chain.

As stated above, recent data suggest that both non-ubiquitinated and monoubiquitinated PEX5 somehow interact with REM components (53, 60). However, the mechanistic meaning of these interactions remains unknown. Given the recent demonstration that the yeast PEX1.PEX6 complex uses a threading mechanism to unfold a substrate (42), we reasoned that assessing whether or not DTM-embedded Ub-PEX5 is globally unfolded during the extraction step would shed light on this issue.

Two strategies were used for this purpose. In the first, we used the classical approach of fusing DHFR to a reporter protein that is used as the substrate in a process requiring unfolding of its polypeptide chain (61). This approach explores the fact that DHFR is a relatively pliable protein that can be unfolded by several molecular machineries, including ATPases of the AAA family (62, 63). However, this property changes completely in the presence of methotrexate (MTX), a folate analog that binds to DHFR greatly stabilizing its structure (64). We produced a fusion protein comprising the first 324 amino acid residues of PEX5(C11K) followed by mouse DHFR (PEX5(1-324;C11K)-DHFR) and used this protein, as well as PEX5(1-324;C11K), in two-step *in vitro* import/export assays, which were done either in the presence or in the absence of MTX (see experimental procedures for details). As expected, MTX did not block export of monoubiquitinated PEX5(1-324;C11K); as shown in Fig. 4A (panel III), a considerable fraction of Ub-PEX5(1-324;C11K) was found in the soluble phase of the MTX-containing assay after incubation in the presence of ATP but not AMP-PNP (compare lanes 4 and 6; see also Fig. 2A). A similar behavior was observed for Ub-PEX5(1-324;C11K)-DHFR in the assay lacking MTX (Fig. 4A, panel I), although the export efficiency of this species seems to be already compromised (see legend to Fig. 4 for a quantification of export efficiencies). Importantly, in the presence of MTX and ATP, export of Ub-PEX5(1-324;C11K)-DHFR was strongly inhibited (Fig. 4A, panel II, compare lanes 4 and 6). Furthermore, under these conditions organelle-associated monoubiquitinated PEX5(1-324;C11K)-DHFR

was mostly accessible to exogenously added proteinase K, indicating that the export step was blocked at a late stage (Fig. 4B). Thus, as previously described for a PEX5-EGFP fusion protein (51), the ATP-dependent dislocation of this species by the REM can be initiated but not terminated efficiently. Besides confirming that the identity of PEX5 C-terminus is irrelevant for the initiation of the extraction step, these findings indicate that an irrelevant protein domain appended to the C-terminus of the receptor inhibits its release by the REM, particularly if that domain is tightly folded.

In the second approach we adapted an elegant assay recently developed for the yeast PEX1.PEX6 complex which monitors global unfolding of a protein substrate by determining the accessibility of its cysteine residues to maleimide-containing reagents (42). Full-length PEX5(C11K), which possesses 5 relatively unexposed cysteines at its C-terminal TPR domain ((65); see also Fig. 1), and PEG-maleimide of 5 kDa were used in these experiments. Again, a two-step import/export protocol was used. Briefly, an organelle pellet containing DTM-embedded Ub-PEX5 was resuspended in import buffer and divided into three aliquots. One aliquot received ATP γ S, to maintain the REM blocked (29), plus PEG-maleimide and was incubated for 3 min at 37 °C. The second aliquot received PEG-maleimide plus a 2:1 ATP:ATP γ S mixture and was also incubated for 3 min at 37 °C (note: ATP alone also works in this experiment (data not shown), but the PEGylation yields are slightly better with this mixture, presumably because it decreases the export rate); the third aliquot received the 2:1 ATP:ATP γ S mixture, and after a 10 min-incubation at 37 °C (to release Ub-PEX5 into the soluble phase of the assay) was treated for an additional 3 min at 37 °C with PEG-maleimide. After quenching unreacted PEG-maleimide with an excess of DTT, organelles and soluble proteins were then separated by centrifugation and both were analyzed by SDS-PAGE/autoradiography. As shown in Fig. 5, Ub-PEX5 arrested at the DTM (lane 2) was not PEGylated whereas only a small fraction of already released (soluble) Ub-PEX5 (lane 7) was PEGylated during the 3-min incubation. In contrast, the presence of PEG-maleimide during the 3-min export step led to an almost quantitative PEGylation of Ub-PEX5 (lane 5). Altogether, these data strongly suggest that extraction of Ub-PEX5 from the peroxisomal

DTM involves unfolding of its polypeptide chain.

DISCUSSION

It is long known that extraction of Ub-PEX5 from the peroxisomal DTM is an ATP-dependent process that requires the AAA ATPases PEX1.PEX6 (27, 30, 31) but how exactly this occurs has remained mysterious. A priori, and as discussed before (50), there are two possibilities: 1) the REM could interact with Ub-PEX5 and pull it from the DTM releasing it into the cytosol or 2) the REM could bind and unfold/sequester DTM components that interact with Ub-PEX5, thus disrupting all the interactions that maintain the receptor at the peroxisomal membrane. Although the first possibility is conceptually more straightforward, recent data on yeast and mammalian PEX1 and PEX6 proteins could actually support the second mechanism. We are referring to the fact that *in vitro* the yeast PEX1.PEX6 complex can bind and unfold a soluble fragment of PEX15, the yeast orthologue of mammalian PEX26, but not a linear ubiquitin-PEX5 fusion protein, and to the findings that both mammalian and yeast PEX1.PEX6 complexes interact with the PEX5.PEX14 complex via PEX26 and PEX15, respectively (42, 60). Together, these data might suggest that the interaction between PEX5 and PEX14, the main PEX5-binding component of the DTM, is disrupted by the PEX1.PEX6 complex via PEX15/PEX26 (42). Although such a mechanism is plausible, the data supporting it can actually be interpreted differently. Indeed, as recently discussed by Gardner and colleagues (42), the interaction between PEX15/PEX26 and the PEX5.PEX14 complex may simply reflect a role of PEX15/PEX26 in recruiting Ub-PEX5 to the PEX1.PEX6 complex, and the fact that the yeast PEX1.PEX6 complex does not unfold a soluble linear ubiquitin-PEX5 fusion protein *in vitro* could mean that the AAA complex recognizes only correctly monoubiquitinated PEX5 (*i.e.*, PEX5 ubiquitinated at its residue 11) or that the interaction between the PEX1.PEX6 complex and PEX5 requires other peroxins, which were not present in those *in vitro* assays. Finally, the fact that yeast PEX1.PEX6 unfolds a C-terminally truncated PEX15 protein *in vitro* does not necessarily mean that it does so with full-length PEX15 *in vivo*, particularly when we consider that the free disordered C-terminal end of the recombinant PEX15 fragment engaged by

the PEX1.PEX6 complex in those *in vitro* assays corresponds to an internal domain in the membrane embedded full-length PEX15 protein. Clearly, additional work was necessary to clarify this issue.

Here, we used an established cell-free *in vitro* system to address this problem. We provide evidence strongly supporting the view that mammalian Ub-PEX5 is a bona fide substrate of the REM. Indeed, we found that DTM-embedded Ub-PEX5 can be photocrosslinked to both PEX1 and PEX6. This suggests that Ub-PEX5 interacts directly with the AAA ATPases of the REM, an expected property for an authentic substrate. More importantly, we have shown that 1) PEX5 cysteine residues located dozens/hundreds residues apart from the pentapeptide motifs that mediate the interaction of PEX5 with the DTM (see Fig. 1) become largely exposed to a maleimide reagent during the ATP-dependent dislocation process, and 2) fusing the N-terminal half of PEX5 (a domain fully functional in both the import and export steps; (50)) to mouse DHFR results in a protein that arrests at the export step particularly when the stability of DHFR is increased by MTX. Thus, together, these results suggest that DTM-embedded Ub-PEX5 undergoes global unfolding during the ATP-dependent extraction process, and that its unfolding is mandatory for a complete extraction from the organelle surface.

Although it is still unclear how DTM-embedded Ub-PEX5 is recruited to the translocation pore of the PEX1.PEX6 hexameric complex, the data presented here, together with previous findings, allow us to propose two hypothetical models. Both take into account that the minimal information necessary to engage the REM resides in the ubiquitin moiety itself plus the region comprising residues 10-125 of PEX5 ((45); and this work). In one model, a protein loop in the 10-125 region of PEX5 would enter the PEX1.PEX6 pore through its cis side (*i.e.*, the membrane-facing side of the PEX1.PEX6 complex). ATP hydrolysis would then lead to the translocation of the remaining Ub-PEX5 domains through the REM pore, ultimately releasing the complete substrate into the cytosol, at the trans side of the PEX1.PEX6 complex. The rather large pore of the PEX1.PEX6 complex, which may widen even more during substrate translocation, as proposed recently for CDC48 (66), together with the finding that PEX5(1-324;C11K)-Ub(1-74) displays no

detectable export problems (see Fig. 2A) might support this possibility.

In the second model, the PEX1.PEX6 ring would assemble around the short exposed segment of PEX5 that follows residue 11 (45). This would place this short segment of PEX5 inside the pore and the ubiquitin moiety of Ub-PEX5 already at the trans side of the PEX1.PEX6 complex. ATP hydrolysis would then lead to the complete dislocation of the PEX5 polypeptide chain into the cytosol. Discriminating between these two possibilities will be a challenging task, but the experimental tools and strategies developed in this work will surely help us to understand this and other still unclear aspects of the peroxisomal matrix protein import machinery.

EXPERIMENTAL PROCEDURES

DNA constructs.

Plasmids encoding the large isoform of human PEX5 possessing a lysine instead of a cysteine residue at position 11 (pGEM4-PEX5(C11K); (35)), a C-terminally truncated form containing residues 1 to 324 (pET28-PEX5(1-324); (67)), a N-terminally truncated form containing residues 315 to 639 (pQE30-PEX5(315-639); (68)), human UCHL3 (pET28a-UCHL3; (69)) and influenza hemagglutinin (HA)-tagged human Ubiquitin (pET28a-HA-Ub; (36)) were described previously. The plasmid pEVOL-pBpF, which encodes the tRNA/tRNA synthetase pair necessary for the *in vivo* incorporation of the photocrosslinker pBpa, in response to an amber codon was a gift from Peter Schultz, USA ((54); Addgene plasmid # 31190).

The PEX5(1-324;C11K) cDNA, encoding amino acid residues 1 to 324 of PEX5(C11K) was obtained by PCR amplification of the plasmid pGEM4-PEX5(C11K) using the primers 5'-GCCCAATACGCAAACCGCCTCTCC-3' and 5'-

GCGCGGATCCTCATTAGTACCCCTTATCATAGGTAGCTG-3'. The purified product was used directly in TNT[®] quick-coupled transcription/translation reactions (see Miscellaneous).

pGEM4-PEX5(10-324;C11K), a plasmid encoding residues 10 to 324 of PEX5(C11K) was obtained by PCR amplification of pGEM4-PEX5(C11K) with primers 5'-GGAATAAGTCGACATGGAAAAGGGGGGT

GC-3' and 5'-CGGGCAGGTCTAGATCAGTACCCCTTATCATAGGTAGC-3'. The purified product was digested and cloned into the *Sall* and *XbaI* sites of pGEM4 (Promega).

A plasmid encoding residues 1 to 324 of PEX5(C11K) fused to the N-terminal of mouse DHFR was obtained as follows. First, DHFR coding region was amplified by PCR using the plasmid pYES2-cytb2(1-107)DHFR ((70); a kind gift of Dr. Dejana Mokranjac, Germany) and the primers 5'-GCGCCGTCTAGAGGATCTGGGGTTCGAC CATTGAACTGCATC-3' and

5'-GCGCGCGGTACCTTAGTCTTTCTTCTCGTAGACTTCAAAC-3'. The purified product was digested and cloned into the *XbaI* and *KpnI* sites of pGEM4 (Promega), originating pGEM4-DHFR. Then, a DNA fragment encoding residues 1 to 324 of PEX5(C11K) was amplified from pGEM4-PEX5(C11K) by PCR with the primers 5'-

GTCTGCCGGTTCGACGCCACCATGGCAAT GCGGGAGCTG-3' and 5'-

GCGCCGTCTAGATCCACTTCCGTACCCCTTATCATAGGTAGCTGACG-3'. The purified fragment was digested and cloned into the *Sall/XbaI*-digest of pGEM4-DHFR, originating pGEM4-PEX5(1-324;C11K)-DHFR.

To obtain a plasmid encoding residues 1 to 324 of PEX5(C11K) fused to human ubiquitin lacking the two C-terminal Gly residues, a DNA fragment encoding residues 1 to 74 of ubiquitin was amplified from pET28a-HA-Ub using the primers 5'-

GCGTACTCTAGAAGCGGCATGCAGATCT TCGTGAAGAC-3' and 5'-

GCTCGCGGTACCTCATCTGAGACGGAGG ACCAG-3'. The purified product was digested and cloned into the *XbaI/KpnI*-digest of pGEM4-PEX5(1-324;C11K)-DHFR, originating pGEM4-PEX5(1-324;C11K)-Ub(1-74).

To generate a plasmid encoding HA-tagged ubiquitin with a C-terminal 6xHistidine-tag (pET28a-HA-Ub-His), the STOP codon of pET28a-HA-Ub was mutated by site-directed mutagenesis (QuikChange II site-directed mutagenesis kit; Agilent Technologies) using the primers 5'-

GTCTCAGAGGTGGTTCAGCGAATTCGAG C-3' and 5'-GCTCGAATTCGCTGAACCACCTCTGAGA C-3'.

Plasmids encoding HA-Ub-His harboring single amber codon mutations (A28X, D39X, Q49X or Q62X) were obtained by site-directed mutagenesis of pET28a-HA-Ub-His with the following primers: 5'-GAGAATGTCAAGTAGAAGATCCAAGACAAGGAAGGC-3' and 5'-GCCTTCCTTGTCTTGGATCTTCTACTTGA CATTCTC-3' for the A28X mutation; 5'-GCATCCCTCCTTAGCAGCAGAGGTTGATC-3' and 5'-GATCAACCTCTGCTGCTAAGGAGGGATG C-3' for the D39X mutation; 5'-CTTTGCTGGGAAATAGCTGGAAGATGGA CGC-3' and 5'-GCGTCCATCTTCCAGCTATTTCCAGCAA AG-3' for the Q49X mutation; and 5'-CTACAACATCTAGAAAGAGTCCACCCTG C-3' and 5'-GCAGGGTGGACTCTTTCTAGATGTTGTAG-3' for the Q62X mutation.

To obtain a plasmid encoding histidine-tagged residues 1 to 421 of human PEX6, the plasmid PTY03 (71) was digested with *NcoI* and the relevant fragment was cloned into the *NcoI* site of pET9dNHis₆ (a kind gift of G. Stier, EMBL, Heidelberg; (72)).

All generated plasmids were sequence-verified.

Expression and purification of recombinant proteins

The histidine-tagged proteins, PEX5(1-324), PEX5(315-639) (hereafter referred to as TPRs) and UCHL3 were purified as described previously (68, 69). All recombinant proteins were stored in Buffer A (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA and 1 mM DTT).

HA-Ub-His was expressed in *Escherichia coli* BL21(DE3) strain by induction with 1 mM isopropyl 1-thio-D-galactopyranoside for 3 h at 37 °C in LB medium. Pelleted cells were resuspended in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM DTT, 50 µg/mL PMSF, 1:500 (v/v) protease inhibitor cocktail (cat. no. P8340, Sigma-Aldrich) and 200 µg/mL lysozyme), incubated on ice for 30 minutes and disrupted by sonication. Histidine-tagged proteins were purified by Ni Sepharose 6 Fast Flow affinity chromatography (GE Healthcare) according to manufacturer instructions. Proteins were concentrated and the buffer exchanged to Buffer A by repeated cycles of centrifugation and dilution using Vivaspin PES concentrator (MWCO 3000 Da, Sartorius).

For incorporation of *pBpa*, HA-Ub-His amber mutants were expressed in BL21(DE3) cells carrying the plasmid pEVOL-*pBpF*. Induction was carried out for 3 h at 37 °C with 1 mM isopropyl 1-thio-D-galactopyranoside and 0.02% arabinose in 2xYT media supplemented with 0.2 mM *pBpa* (cat. no. F-2800; BACHEM). Purification was carried out as above. Histidine-tags were removed from HA-Ub-His fusion proteins by digestion with the deubiquitinating enzyme UCHL3 (10 ng of UCHL3 per µg of HA-Ub-His protein; 1 h at 37 °C).

His-PEX6(1-421) was expressed in *Escherichia coli* BL21(DE3), and purified under denaturing conditions (8 M urea) by Ni-NTA chromatography (Qiagen) with refolding on the column following the manufacturer's instructions.

In vitro peroxisomal import/export assays

In vitro import/export assays of radiolabeled PEX5 proteins were performed as described previously (43). Briefly, 1 to 3 µL of ³⁵S-labeled PEX5 proteins were used in reactions containing 0.6 to 1 mg of a rat liver PNS primed for import (*i.e.*, incubated for 5 min at 37 °C in the presence of 0.4 mM ATP, to free DTMs of endogenous PEX5; (43)) in import buffer (20 mM MOPS-KOH, pH 7.4, 0.25 M sucrose, 50 mM KCl, 3 mM MgCl₂, 20 µM methionine, 2 µg/mL E-64, 2 mM reduced glutathione, 10 µM bovine ubiquitin, final concentration). Reactions were incubated at 37 °C for 20 min in the presence of either 3 mM ATP or AMP-PNP. Reactions were then diluted with SEMK (20 mM MOPS-KOH, pH 7.4, 0.25 M sucrose, 1 mM EDTA-NaOH, pH 8.0, 80 mM KCl) and supernatant and organelle fractions were isolated by centrifugation at ~16.000 g for 15 min at 4 °C. Following protein precipitation with 10% (w/v) trichloroacetic acid, both fractions were analyzed by SDS-PAGE/Western-blot/autoradiography. Where indicated, import reactions were treated with proteinase K exactly as described before (43).

For the two-step assays, radiolabeled PEX5 proteins were first imported in the presence of 3 mM AMP-PNP (1st step) and organelles were isolated as above. Organelle pellets were carefully resuspended in ice-cold import buffer (which in some experiments also contained 0.5 µM BSA and 1 µM recombinant PEX5(1-324)), supplemented with either 3 mM ATP or AMP-PNP and subjected to a second incubation (2nd

step) for 3 min at 37 °C. Soluble and organelle fractions were isolated and analyzed by SDS-PAGE/Western-blot/autoradiography, as described above.

As required, import/export reactions were supplemented with: deubiquitinating-enzyme inhibitor ubiquitin-vinyl methyl ester (2 μM; (36)) to detect Ub-PEX5 in supernatants; recombinant TPRs (1 μM) to inhibit the import of rat endogenous PEX5 during import of C-terminally truncated ³⁵S-PEX5 species; and HA-Ub (WT and pBpa containing mutants (10 μM) in substitution of bovine ubiquitin) for photocrosslinking experiments. MTX, used to impair the export of DHFR fusion PEX5, was added to reticulocyte lysates (pre-incubated for 10 min at 25 °C) and to import reactions at 2 μM.

Photocrosslinking and immunoprecipitation experiments

For photocrosslinking experiments, import reactions of ³⁵S-PEX5(1-324;C11K) were performed in the presence of 3 mM AMP-PNP and either HA-tagged wild-type or mutant ubiquitins containing a photoreactive pBpa residue. Following import (37 °C for 30 min), reactions were halved and put on ice. One half was exposed to UV light (30 min on ice, Blak-ray™ B-100AP 100W lamp, ~7 cm distance). Organelles from both halves were then isolated by centrifugation and analyzed by SDS-PAGE/Western-blot/autoradiography, as previously described.

To immunoprecipitate crosslinked products, organelle fractions of UV irradiated import reactions were solubilized in 50 mM Tris, pH 8.0, 1 mM DTT, 1% SDS for 10 min at 65 °C, and later diluted to RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% DOC, 0.1% SDS, final concentration) supplemented with 1:200 (v/v) protease inhibitor cocktail. The lysate was clarified by centrifugation through a cellulose acetate membrane (Corning® Costar® Spin-X® 0.22 μm) and incubated (3 h at 4 °C) with 50 μL (bed volume) of G protein-coupled sepharose pre-loaded with either anti-PEX1, anti-PEX6 or

control rabbit immunoglobulins. Beads were then washed 3 times with 1 mL of RIPA buffer and once with 1 mL of Tris buffered saline (50 mM Tris, pH 7.4, 150 mM NaCl). Bound proteins were eluted with Laemmli sample buffer. Total, unbound and 5 equivalents of bound protein fractions were subjected to SDS-PAGE/Western blot and autoradiography.

PEGylation susceptibility assays

For the PEGylation assays, organelles derived from ³⁵S-PEX5(C11K) import reactions made in the presence of 3 mM ATPγS were resuspended in import buffer containing either 3 mM ATPγS (export remains blocked) or a mixture of 2 mM ATP plus 1 mM ATPγS (export can occur). Methoxy-PEG-maleimide 5,000 Da (cat.no. 63187, Sigma-Aldrich) was added at 4 mM (final concentration) either immediately before incubating at 37 °C for 3 min, or after Ub-PEX5(C11K) was exported into the soluble fraction by a 10 min incubation at 37 °C. PEG-maleimide was allowed to react only during 3 min before quenching with 100 mM DTT (final concentration) for 3 min at 37 °C. Reactions were diluted with ice-cold SEMK, centrifuged to isolate organelle and supernatant fractions, and processed for SDS-PAGE/Western-blot/autoradiography.

Miscellaneous

³⁵S-Labeled proteins were synthesized in rabbit reticulocyte lysates using the TNT® quick-coupled transcription/translation system (Promega) in the presence of EasyTag™ L-[³⁵S]methionine (specific activity, >1000 Ci/mmol; PerkinElmer Life Sciences) following the manufacturer's instructions.

The antibody against ABCD3 (73) was kindly provided by Dr. Wilhelm W. Just (University of Heidelberg, Germany). The anti-PEX6 antibody was raised in rabbit against human His-PEX6(1-421). Rabbit Polyclonal Anti-PEX1 Antibody (NBP1-80577; Novus Biologicals) was purchased. All primary antibodies were detected with goat alkaline phosphatase-conjugated anti-rabbit antibodies (A9919; Sigma-Aldrich).

ACKNOWLEDGMENTS

The authors thank Britta Moellers (Ruhr-Universität Bochum, Germany) for providing plasmids and recombinant protein for the generation of the anti-PEX6 antibody. This work was funded by FEDER (Fundo Europeu de Desenvolvimento Regional), through COMPETE 2020 – Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through Fundação para a Ciência e Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Inovação in the framework of the projects “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274) and “The molecular mechanisms of peroxisome biogenesis” (PTDC/BEX-BCM/2311/2014), and through Norte 2020 – Programa Operacional Regional do Norte, under the application of the “Porto Neurosciences and Neurologic Disease Research Initiative at i3S” (NORTE-01-0145-FEDER-000008). A.G.P, T.F., D.B., A.F.D., A.B.B. and T.A.R. are supported by Fundação para a Ciência e Tecnologia, Programa Operacional Potencial Humano do QREN and Fundo Social Europeu.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest with the contents of this article.

REFERENCES

1. Islinger, M., Cardoso, M. J. R., and Schrader, M. (2010) Be different--the diversity of peroxisomes in the animal kingdom. *Biochim. Biophys. Acta.* **1803**, 881–97
2. Van Veldhoven, P. P. (2010) Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. *J. Lipid Res.* **51**, 2863–95
3. Kikuchi, M., Hatano, N., Yokota, S., Shimozawa, N., Imanaka, T., and Taniguchi, H. (2004) Proteomic analysis of rat liver peroxisome: presence of peroxisome-specific isozyme of Lon protease. *J. Biol. Chem.* **279**, 421–8
4. Wiese, S., Gronemeyer, T., Ofman, R., Kunze, M., Grou, C. P., Almeida, J. A., Eisenacher, M., Stephan, C., Hayen, H., Schollenberger, L., Korosec, T., Waterham, H. R., Schliebs, W., Erdmann, R., Berger, J., Meyer, H. E., Just, W., Azevedo, J. E., Wanders, R. J. A., and Warscheid, B. (2007) Proteomics characterization of mouse kidney peroxisomes by tandem mass spectrometry and protein correlation profiling. *Mol. Cell. Proteomics.* **6**, 2045–57
5. Islinger, M., Grille, S., Fahimi, H. D., and Schrader, M. (2012) The peroxisome: an update on mysteries. *Histochem. Cell Biol.* **137**, 547–74
6. Wanders, R. J. A. (2014) Metabolic functions of peroxisomes in health and disease. *Biochimie.* **98**, 36–44
7. Waterham, H. R., Ferdinandusse, S., and Wanders, R. J. A. (2016) Human disorders of peroxisome metabolism and biogenesis. *Biochim. Biophys. Acta.* **1863**, 922–33
8. Distel, B., Erdmann, R., Gould, S. J., Blobel, G. G., Crane, D. I., Cregg, J. M., Dodt, G., Fujiki, Y., Goodman, J. M., Just, W. W., Kiel, J. A. K. W., Kunau, W. H., Lazarow, P. B., Mannaerts, G. P., Moser, H. W., Osumi, T., Rachubinski, R. a., Roscher, A., Subramani, S., Tabak, H. F., Tsukamoto, T., Valle, D., Van Der Klei, I., Van Veldhoven, P. P., Veenhuis, M., Klei, I. Van Der, Veldhoven, P. P. Van, and Veenhuis, M. (1996) A Unified Nomenclature for Peroxisome Biogenesis Factors. *J. Cell Biol.* **135**, 1–3
9. Francisco, T., Rodrigues, T. A. T. A., Dias, A. F. A. F., Barros-Barbosa, A., Bicho, D., and Azevedo, J. E. J. E. (2017) Protein transport into peroxisomes: Knowns and unknowns. *BioEssays.* **39**, doi: 10.1002/bies.201700047.
10. Otera, H., Okumoto, K., Tateishi, K., Ikoma, Y., Matsuda, E., Nishimura, M., Tsukamoto, T., Osumi, T., Ohashi, K., Higuchi, O., and Fujiki, Y. (1998) Peroxisome targeting signal type 1 (PTS1) receptor is involved in import of both PTS1 and PTS2: studies with PEX5-defective CHO cell mutants. *Mol. Cell. Biol.* **18**, 388–99
11. Braverman, N., Dodt, G., Gould, S. J., and Valle, D. (1998) An isoform of pex5p, the human PTS1 receptor, is required for the import of PTS2 proteins into peroxisomes. *Hum. Mol. Genet.* **7**, 1195–205
12. Wiemer, E. A., Nuttley, W. M., Bertolaet, B. L., Li, X., Francke, U., Wheelock, M. J., Anné, U. K., Johnson, K. R., and Subramani, S. (1995) Human peroxisomal targeting signal-1 receptor restores peroxisomal protein import in cells from patients with fatal peroxisomal

- disorders. *J. Cell Biol.* **130**, 51–65
13. Galland, N., Demeure, F., Hannaert, V., Verplaetse, E., Vertommen, D., Van der Smissen, P., Courtoy, P. J., and Michels, P. A. M. (2007) Characterization of the role of the receptors PEX5 and PEX7 in the import of proteins into glycosomes of *Trypanosoma brucei*. *Biochim. Biophys. Acta.* **1773**, 521–35
 14. McCollum, D., Monosov, E., and Subramani, S. (1993) The pas8 mutant of *Pichia pastoris* exhibits the peroxisomal protein import deficiencies of Zellweger syndrome cells--the PAS8 protein binds to the COOH-terminal tripeptide peroxisomal targeting signal, and is a member of the TPR protein family. *J. Cell Biol.* **121**, 761–74
 15. Van der Klei, I. J., Hilbrands, R. E., Swaving, G. J., Waterham, H. R., Vrieling, E. G., Titorenko, V. I., Cregg, J. M., Harder, W., and Veenhuis, M. (1995) The *Hansenula polymorpha* PER3 gene is essential for the import of PTS1 proteins into the peroxisomal matrix. *J. Biol. Chem.* **270**, 17229–36
 16. Van der Leij, I., Franse, M. M., Elgersma, Y., Distel, B., and Tabak, H. F. (1993) PAS10 is a tetratricopeptide-repeat protein that is essential for the import of most matrix proteins into peroxisomes of *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci.* **90**, 11782–6
 17. Kragler, F., Lametschwandtner, G., Christmann, J., Hartig, A., and Harada, J. J. (1998) Identification and analysis of the plant peroxisomal targeting signal 1 receptor NtPEX5. *Proc. Natl. Acad. Sci.* **95**, 13336–41
 18. Jardim, A., Liu, W., Zheleznova, E., and Ullman, B. (2000) Peroxisomal targeting signal-1 receptor protein PEX5 from *Leishmania donovani*. Molecular, biochemical, and immunocytochemical characterization. *J. Biol. Chem.* **275**, 13637–44
 19. Bhogal, M. S., Lanyon-Hogg, T., Johnston, K. A., Warriner, S. L., and Baker, A. (2016) Covalent Label Transfer between Peroxisomal Importomer Components Reveals Export-driven Import Interactions. *J. Biol. Chem.* **291**, 2460–8
 20. Fransen, M., Brees, C., Baumgart, E., Vanhooren, J. C. T., Baes, M., Mannaerts, G. P., and Van Veldhoven, P. P. (1995) Identification and characterization of the putative human peroxisomal C-terminal targeting signal import receptor. *J. Biol. Chem.* **270**, 7731–7736
 21. Reguenga, C., Oliveira, M. E., Gouveia, A. M., Sá-Miranda, C., and Azevedo, J. E. (2001) Characterization of the mammalian peroxisomal import machinery: Pex2p, Pex5p, Pex12p, and Pex14p are subunits of the same protein assembly. *J. Biol. Chem.* **276**, 29935–42
 22. Agne, B., Meindl, N. M., Niederhoff, K., Einwächter, H., Rehling, P., Sickmann, A., Meyer, H. E., Girzalsky, W., and Kunau, W. H. (2003) Pex8p: an intraperoxisomal organizer of the peroxisomal import machinery. *Mol. Cell.* **11**, 635–46
 23. Francisco, T., Rodrigues, T. A., Freitas, M. O., Grou, C. P., Carvalho, A. F., Sá-Miranda, C., Pinto, M. P., and Azevedo, J. E. (2013) A cargo-centered perspective on the PEX5-mediated peroxisomal protein import pathway. *J. Biol. Chem.* **288**, 29151–29159
 24. Rodrigues, T. A., Alencastre, I. S., Francisco, T., Brites, P., Fransen, M., Grou, C. P., and Azevedo, J. E. (2014) A PEX7-centered perspective on the peroxisomal targeting signal type 2-mediated protein import pathway. *Mol. Cell. Biol.* **34**, 2917–28
 25. Alencastre, I. S., Rodrigues, T. A., Grou, C. P., Fransen, M., Sá-Miranda, C., and Azevedo, J. E. (2009) Mapping the cargo protein membrane translocation step into the PEX5 cycling pathway. *J. Biol. Chem.* **284**, 27243–51
 26. Gouveia, A. M., Guimarães, C. P., Oliveira, M. E., Sá-Miranda, C., and Azevedo, J. E. (2003) Insertion of Pex5p into the peroxisomal membrane is cargo protein-dependent. *J. Biol. Chem.* **278**, 4389–92
 27. Oliveira, M. E., Gouveia, A. M., Pinto, R. A., Sá-Miranda, C., and Azevedo, J. E. (2003) The energetics of Pex5p-mediated peroxisomal protein import. *J. Biol. Chem.* **278**, 39483–8
 28. Williams, C., Van Den Berg, M., Sprenger, R. R., and Distel, B. (2007) A conserved cysteine is essential for Pex4p-dependent ubiquitination of the peroxisomal import receptor Pex5p. *J. Biol. Chem.* **282**, 22534–43
 29. Carvalho, A. F., Pinto, M. P., Grou, C. P., Alencastre, I. S., Fransen, M., Sá-Miranda, C., and Azevedo, J. E. (2007) Ubiquitination of mammalian Pex5p, the peroxisomal import receptor. *J. Biol. Chem.* **282**, 31267–72
 30. Miyata, N., and Fujiki, Y. (2005) Shuttling Mechanism of Peroxisome Targeting Signal Type

- 1 Receptor Pex5 : ATP-Independent Import and ATP-Dependent Export. *Mol. Cell. Biol.* **25**, 10822–10832
31. Platta, H. W., Grunau, S., Rosenkranz, K., Girzalsky, W., and Erdmann, R. (2005) Functional role of the AAA peroxins in dislocation of the cycling PTS1 receptor back to the cytosol. *Nat. Cell Biol.* **7**, 817–22
 32. Goto, S., Mano, S., Nakamori, C., and Nishimura, M. (2011) Arabidopsis ABERRANT PEROXISOME MORPHOLOGY9 is a peroxin that recruits the PEX1-PEX6 complex to peroxisomes. *Plant Cell.* **23**, 1573–87
 33. Tamura, S., Yasutake, S., Matsumoto, N., and Fujiki, Y. (2006) Dynamic and functional assembly of the AAA peroxins, Pex1p and Pex6p, and their membrane receptor Pex26p. *J. Biol. Chem.* **281**, 27693–704
 34. Birschmann, I., Stroobants, A. K., Berg, M. Van Den, Schafer, A., Rosenkranz, K., Kunau, W.-H., Tabak, H. F., van den Berg, M., Schafer, A., Rosenkranz, K., Kunau, W.-H., and Tabak, H. F. (2003) Pex15p of *Saccharomyces cerevisiae* Provides a Molecular Basis for Recruitment of the AAA Peroxin Pex6p to Peroxisomal Membranes. *Mol. Biol. Cell.* **14**, 2226–2236
 35. Grou, C. P., Carvalho, A. F., Pinto, M. P., Huybrechts, S. J., Sá-Miranda, C., Fransen, M., and Azevedo, J. E. (2009) Properties of the ubiquitin-pex5p thiol ester conjugate. *J. Biol. Chem.* **284**, 10504–13
 36. Grou, C. P., Francisco, T., Rodrigues, T. A., Freitas, M. O., Pinto, M. P., Carvalho, A. F., Domingues, P., Wood, S. A., Rodríguez-Borges, J. E., Sá-Miranda, C., Fransen, M., and Azevedo, J. E. (2012) Identification of ubiquitin-specific protease 9X (USP9X) as a deubiquitinase acting on the ubiquitin-peroxin 5 (PEX5) thioester conjugate. *J. Biol. Chem.* **287**, 12815–27
 37. Debelyy, M. O., Platta, H. W., Saffian, D., Hensel, A., Thoms, S., Meyer, H. E., Warscheid, B., Girzalsky, W., and Erdmann, R. (2011) Ubp15p, a ubiquitin hydrolase associated with the peroxisomal export machinery. *J. Biol. Chem.* **286**, 28223–28234
 38. Tan, D., Blok, N. B., Rapoport, T. A., and Walz, T. (2016) Structures of the double-ring AAA ATPase Pex1-Pex6 involved in peroxisome biogenesis. *FEBS J.* **283**, 986–92
 39. Gardner, B. M., Chowdhury, S., Lander, G. C., and Martin, A. (2015) The Pex1/Pex6 complex is a heterohexameric AAA+ motor with alternating and highly coordinated subunits. *J. Mol. Biol.* **427**, 1375–88
 40. Ciniawsky, S., Grimm, I., Saffian, D., Girzalsky, W., Erdmann, R., and Wendler, P. (2015) Molecular snapshots of the Pex1/6 AAA+ complex in action. *Nat. Commun.* **6**, 7331
 41. Blok, N. B., Tan, D., Wang, R. Y.-R., Penczek, P. A., Baker, D., DiMaio, F., Rapoport, T. A., and Walz, T. (2015) Unique double-ring structure of the peroxisomal Pex1/Pex6 ATPase complex revealed by cryo-electron microscopy. *Proc. Natl. Acad. Sci.* **112**, E4017-25
 42. Gardner, B. M., Castanzo, D. T., Chowdhury, S., Stjepanovic, G., Stefely, M. S., Hurley, J. H., Lander, G. C., and Martin, A. (2018) The peroxisomal AAA-ATPase Pex1/Pex6 unfolds substrates by processive threading. *Nat. Commun.* **9**, 135
 43. Rodrigues, T. A. T. A., Francisco, T., Dias, A. F. A. F., Pedrosa, A. G. A. G., Grou, C. P. C. P., and Azevedo, J. E. J. E. (2016) A cell-free organelle-based in vitro system for studying the peroxisomal protein import machinery. *Nat. Protoc.* **11**, 2454–2469
 44. Haas, A. L., Warmes, J., and Rose, I. A. (1983) Ubiquitin adenylate: structure and role in ubiquitin activation. *Biochemistry.* **22**, 4388–94
 45. Dias, A. F. A. F., Rodrigues, T. A. T. A., Pedrosa, A. G. A. G., Barros-Barbosa, A., Francisco, T., and Azevedo, J. E. J. E. (2017) The peroxisomal matrix protein translocon is a large cavity-forming protein assembly into which PEX5 protein enters to release its cargo. *J. Biol. Chem.* **292**, 15287–15300
 46. Baker, T. A., and Sauer, R. T. (2012) ClpXP, an ATP-powered unfolding and protein-degradation machine. *Biochim. Biophys. Acta.* **1823**, 15–28
 47. Bailey, M. E., Sackett, D. L., and Ross, J. L. (2015) Katanin Severing and Binding Microtubules Are Inhibited by Tubulin Carboxy Tails. *Biophys. J.* **109**, 2546–61
 48. Johjima, A., Noi, K., Nishikori, S., Ogi, H., Esaki, M., and Ogura, T. (2015) Microtubule severing by katanin p60 AAA+ ATPase requires the C-terminal acidic tails of both α - and β -

- tubulins and basic amino acid residues in the AAA+ ring pore. *J. Biol. Chem.* **290**, 11762–70
49. Monroe, N., and Hill, C. P. (2016) Meiotic Clade AAA ATPases: Protein Polymer Disassembly Machines. *J. Mol. Biol.* **428**, 1897–911
 50. Costa-Rodrigues, J., Carvalho, A. F., Gouveia, A. M., Fransén, M., Sá-Miranda, C., and Azevedo, J. E. (2004) The N terminus of the peroxisomal cycling receptor, Pex5p, is required for redirecting the peroxisome-associated peroxin back to the cytosol. *J. Biol. Chem.* **279**, 46573–9
 51. Nordgren, M., Francisco, T., Lismont, C., Hennebel, L., Brees, C., Wang, B., Van Veldhoven, P. P., Azevedo, J. E., and Fransén, M. (2015) Export-deficient monoubiquitinated PEX5 triggers peroxisome removal in SV40 large T antigen-transformed mouse embryonic fibroblasts. *Autophagy*. **11**, 1326–40
 52. Gouveia, A. M., Guimarães, C. P., Oliveira, M. E., Reguenga, C., Sá-Miranda, C., and Azevedo, J. E. (2003) Characterization of the peroxisomal cycling receptor, Pex5p, using a cell-free in vitro import system. *J. Biol. Chem.* **278**, 226–32
 53. Miyata, N., Okumoto, K., Mukai, S., Noguchi, M., and Fujiki, Y. (2012) AWP1/ZFAND6 functions in Pex5 export by interacting with cys-monoubiquitinated Pex5 and Pex6 AAA ATPase. *Traffic*. **13**, 168–83
 54. Chin, J. W., Martin, A. B., King, D. S., Wang, L., and Schultz, P. G. (2002) Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli. *Proc. Natl. Acad. Sci.* **99**, 11020–4
 55. Young, T. S., Ahmad, I., Yin, J. A., and Schultz, P. G. (2010) An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coli. *J. Mol. Biol.* **395**, 361–374
 56. Reuber, B. E., Germain-Lee, E., Collins, C. S., Morrell, J. C., Ameritunga, R., Moser, H. W., Valle, D., and Gould, S. J. (1997) Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. *Nat. Genet.* **17**, 445–448
 57. Tsukamoto, T., Miura, S., Nakai, T., Yokota, S., Shimozawa, N., Suzuki, Y., Orii, T., Fujiki, Y., Sakai, F., Bogaki, A., Yasumo, H., and Osumi, T. (1995) Peroxisome assembly factor-2, a putative ATPase cloned by functional complementation on a peroxisome-deficient mammalian cell mutant. *Nat. Genet.* **11**, 395–401
 58. Portsteffen, H., Beyer, A., Becker, E., Epplen, C., Pawlak, A., Kunau, W.-H., and Dodt, G. (1997) Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders. *Nat. Genet.* **17**, 449–452
 59. Dormán, G., Nakamura, H., Pulsipher, A., and Prestwich, G. D. (2016) The Life of Pi Star: Exploring the Exciting and Forbidden Worlds of the Benzophenone Photophore. *Chem. Rev.* **116**, 15284–15398
 60. Tamura, S., Matsumoto, N., Takebas, R., and Fujiki, Y. (2014) AAA peroxins and their recruiter Pex26p modulate the interactions of peroxins involved in peroxisomal protein import. *J. Biol. Chem.* **289**, 24336–24346
 61. Eilers, M., and Schatz, G. (1986) Binding of a specific ligand inhibits import of a purified precursor protein into mitochondria. *Nature*. **322**, 228–32
 62. Lee, C., Schwartz, M. P., Prakash, S., Iwakura, M., and Matouschek, A. (2001) ATP-dependent proteases degrade their substrates by processively unraveling them from the degradation signal. *Mol. Cell*. **7**, 627–37
 63. Johnston, J. A., Johnson, E. S., Waller, P. R., and Varshavsky, A. (1995) Methotrexate inhibits proteolysis of dihydrofolate reductase by the N-end rule pathway. *J. Biol. Chem.* **270**, 8172–8
 64. Junker, J. P., Hell, K., Schlierf, M., Neupert, W., and Rief, M. (2005) Influence of substrate binding on the mechanical stability of mouse dihydrofolate reductase. *Biophys. J.* **89**, L46–8
 65. Gatto, G., Geisbrecht, B., Gould, S. J., and Berg, J. M. (2000) Peroxisomal targeting signal-1 recognition by the TPR domains of human PEX5. *Nat. Struct. Biol.* **7**, 1091–1095
 66. Bodnar, N. O., and Rapoport, T. A. (2017) Molecular Mechanism of Substrate Processing by the Cdc48 ATPase Complex. *Cell*. **169**, 722–735
 67. Grou, C. P., Carvalho, A. F., Pinto, M. P., Wiese, S., Piechura, H., Meyer, H. E., Warscheid, B., Sá-Miranda, C., and Azevedo, J. E. (2008) Members of the E2D (UbcH5) family mediate the ubiquitination of the conserved cysteine of Pex5p, the peroxisomal import receptor. *J. Biol. Chem.* **283**, 14190–7

68. Carvalho, A. F., Costa-Rodrigues, J., Correia, I., Costa Pessoa, J., Faria, T. Q., Martins, C. L., Fransen, M., Sá-Miranda, C., and Azevedo, J. E. (2006) The N-terminal half of the peroxisomal cycling receptor Pex5p is a natively unfolded domain. *J. Mol. Biol.* **356**, 864–75
69. Grou, C. P., Pinto, M. P., Mendes, A. V., Domingues, P., and Azevedo, J. E. (2015) The de novo synthesis of ubiquitin: identification of deubiquitinases acting on ubiquitin precursors. *Sci. Rep.* **5**, 12836
70. Popov-Čeleketić, D., Waegemann, K., Mapa, K., Neupert, W., and Mokranjac, D. (2011) Role of the import motor in insertion of transmembrane segments by the mitochondrial TIM23 complex. *EMBO Rep.* **12**, 542–548
71. Yahraus, T., Braverman, N., Dodt, G., Kalish, J. E., Morrell, J. C., Moser, H. W., Valle, D., and Gould, S. J. (1996) The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. *EMBO J.* **15**, 2914–23
72. Walter, C., Gootjes, J., Mooijer, P. A., Portsteffen, H., Klein, C., Waterham, H. R., Barth, P. G., Epplen, J. T., Kunau, W. H., Wanders, R. J., and Dodt, G. (2001) Disorders of peroxisome biogenesis due to mutations in PEX1: phenotypes and PEX1 protein levels. *Am. J. Hum. Genet.* **69**, 35–48
73. Koster, A., Heisig, M., Heinrich, P. C., and Just, W. W. (1986) IN VITRO SYNTHESIS OF PEROXISOMAL MEMBRANE POLYPEPTIDES. *Biochem. Biophys. Res. Commun.* **137**, 626–632
74. Otera, H., Setoguchi, K., Hamasaki, M., Kumashiro, T., Shimizu, N., and Fujiki, Y. (2002) Peroxisomal targeting signal receptor Pex5p interacts with cargoes and import machinery components in a spatiotemporally differentiated manner: conserved Pex5p WXXXF/Y motifs are critical for matrix protein import. *Mol. Cell. Biol.* **22**, 1639–1655
75. Neuhaus, A., Kooshapur, H., Wolf, J., Meyer, N. H., Madl, T., Saidowsky, J., Hambruch, E., Lazam, A., Jung, M., Sattler, M., Schliebs, W., and Erdmann, R. (2014) A novel Pex14 protein-interacting site of human Pex5 is critical for matrix protein import into peroxisomes. *J. Biol. Chem.* **289**, 437–48
76. Dodt, G., Warren, D., Becker, E., Rehling, P., and Gould, S. J. (2001) Domain mapping of human PEX5 reveals functional and structural similarities to *Saccharomyces cerevisiae* Pex18p and Pex21p. *J. Biol. Chem.* **276**, 41769–81
77. Vijay-Kumar, S., Bugg, C. E., and Cook, W. J. (1987) Structure of ubiquitin refined at 1.8 Å resolution. *J. Mol. Biol.* **194**, 531–44
78. Carvalho, A. F., Grou, C. P., Pinto, M. P., Alencastre, I. S., Costa-Rodrigues, J., Fransen, M., Sá-Miranda, C., and Azevedo, J. E. (2007) Functional characterization of two missense mutations in Pex5p - C11S and N526K. *Biochim. Biophys. Acta.* **1773**, 1141–8

FOOTNOTES

The abbreviations used are: AAA, ATPases Associated with diverse cellular Activities; DHFR, dihydrofolate reductase; DTM, docking/translocation module; EGFP, enhanced GFP; HA, influenza hemagglutinin; MTX, methotrexate; *pBpa*, *p*-Benzoyl-1-Phenylalanine; PNS, post-nuclear supernatant; REM, receptor export module; Ub-PEX5, monoubiquitinated PEX5.

FIGURE LEGENDS

Figure 1. Schematic representation of PEX5 species used in this work. The C11K substitution, the PEX13- and PEX14-binding pentapeptide motifs (black bars; (74, 75)), the PEX7-binding domain (gray box; (76)), the PTS1-binding tetratricopeptide repeats (Zigzag boxes; (65)), and the 5 cysteine residues present in PEX5(C11K) (black dots) are indicated. Ub, ubiquitin; DHFR, dihydrofolate reductase. Abbreviated names of the different PEX5 species, as used throughout the figures, are shown in quotation marks.

Figure 2. Neither the N- nor the C-terminus of DTM-embedded Ub-PEX5 is important for the export step. A, PEX5(1-324;C11K) containing a ubiquitin moiety at its C-terminus is extracted by the REM. Organelles from a PEX5(1-324;C11K)-Ub(1-74) (P5Δ-UbΔ) or PEX5(1-324;C11K) (P5Δ) import reaction made in the presence of AMP-PNP (Pi; lane 1) were subjected to a second incubation

in the presence of either ATP, to promote export (lanes 2 and 3), or AMP-PNP to maintain the REM blocked (lanes 4 and 5). Organelle (PE; lanes 2 and 4) and soluble fractions (SE; lanes 3 and 5) were then analyzed by SDS-PAGE/Western-blot/autoradiography. A representative experiment (n=3) is shown. The distribution of the peroxisomal membrane protein ABCD3 is shown. Lane I, 5% of the indicated radiolabeled protein used in the assay. **B**, The first nine amino acid residues of PEX5 are not required for its export. Radiolabeled PEX5(10-324;C11K) (Δ P5 Δ) or PEX5(1-324;C11K) (P5 Δ) were subjected to a single-step assay in the presence of either AMP-PNP or ATP, as indicated. Organelle pellets (P) and supernatants (S) were then analyzed by SDS-PAGE/Western-blot/autoradiography. A representative experiment (n=3) is shown. Immunoblot against ABCD3 is shown. *, unspecific proteins occasionally recognized by the ABCD3 antibody. Lanes I₁ and I₂, 10% of the indicated radiolabeled protein used in the assay. In A and B, numbers to the left indicate the molecular masses of protein standards in kDa.

Figure 3. Monoubiquitinated PEX5(1-324;C11K) can be specifically photocrosslinked to PEX1 and PEX6 through its ubiquitin moiety. **A**, Ubiquitin structure (PBD:1UBQ; (77)) highlighting the relative positions of the amino acid residues replaced by a photoreactive *p*Bpa. **B**, Radiolabeled PEX5(1-324;C11K) (P5 Δ) was used in import assays containing AMP-PNP and either HA-tagged wild-type (WT) ubiquitin or one of four ubiquitin mutants possessing a single *p*Bpa residue at the indicated position (A28, D39, Q49 or Q62). Import reactions were halved, and irradiated (30' UV) or not (0' UV) with UV light while kept on ice. Organelles were isolated by centrifugation and analyzed by SDS-PAGE/Western-blot/autoradiography. Lane I, 5% of the radiolabeled protein used in each reaction. Major crosslinking products are indicated. Some minor ³⁵S-labeled crosslinked species were also detected; *. One of four experiments with similar results is shown. **C**, Organelle fractions of UV-irradiated import reactions (as shown in B) were solubilized and immunoprecipitated with anti-PEX1 (PEX1), anti-PEX6 (PEX6) or a rabbit control serum (Ctrl, control) in RIPA buffer. Total protein (T), immunoprecipitated protein (IP) and corresponding immunodepleted fractions (ID) were analyzed by SDS-PAGE/Western-blot/autoradiography. Each immunoprecipitation was performed at least twice. Following film exposure, the nitrocellulose membranes were cut slightly above the 116-kDa marker and the upper and lower strips were probed with anti-PEX1 and anti-PEX6 antibodies, respectively (the membrane from the Ub(Q62*p*Bpa) experiment is shown here). In B and C, numbers to the left indicate the molecular masses of protein standards in kDa.

Figure 4. A tightly folded domain appended to the C-terminal of PEX5(1-324;C11K) inhibits its export. **A**, Radiolabeled PEX5(1-324;C11K)-DHFR (P5 Δ -DHFR) and PEX5(1-324;C11K) (P5 Δ) were used in two-step import/export assays carried out in the absence (panel I; -MTX) or presence of 2 μ M methotrexate (panels II and III; +MTX). After the import step, organelles (Pi; lane 2) were separated from the cytosolic fraction (Si; lane 1) and subjected to the 2nd step of the assay in the presence of either ATP (lanes 3 and 4) or AMP-PNP (lanes 5 and 6). Organelles (PE; lanes 3 and 5) and soluble fractions (SE; lanes 4 and 6) were analyzed by SDS-PAGE/Western-blot/autoradiography. Autoradiographs and ABCD3 immunoblots are shown. SI, equivalent to 50 μ g of PNS; Pi, PE and SE, equivalent to 250 μ g of PNS. Lane I, 25% of the radiolabeled protein used in the reactions. *, marks a N-terminally truncated product of PEX5(1-324;C11K)-DHFR that can be imported but not exported (78). The percentages of exported species (defined as the ratio of ubiquitinated species in SE to the sum of ubiquitinated species in SE and PE) were determined by densitometry analyses of three independent experiments. Values of 40% (range 26-47%), 10% (range 7-13%), and 64% (range 53-82%) were obtained for Ub-P5 Δ -DHFR minus MTX, Ub-P5 Δ -DHFR plus MTX, and Ub-P5 Δ plus MTX, respectively. **B**, Radiolabeled PEX5(1-324;C11K)-DHFR (P5 Δ -DHFR) was subjected to single-step assays in the presence of MTX and either ATP or AMP-PNP. After incubation, samples were halved and treated (lanes +) or not (lanes -) with proteinase K (PK). Organelles were isolated and analyzed by SDS-PAGE/Western-blot/autoradiography. I, 5% of the radiolabeled protein used in the assay. The autoradiograph (upper panel) and the corresponding Ponceau S-stained membrane (lower panel) of a representative experiment (n=3) are shown. *, as in A. Numbers to the left indicate the molecular masses of protein standards in kDa.

Figure 5. Buried cysteine residues present in the C-terminal half of PEX5 become exposed during the export step. Full length PEX5(C11K) (P5) was subjected to import reactions in the presence of ATP γ S. Isolated organelles (Pi) were resuspended and used in three different export assays, performed in the presence of ATP γ S (export blocked) or a 2:1 ATP:ATP γ S mixture (export induced). PEG-maleimide 5,000 Da (PEG-mal) was added either immediately before or after Ub-PEX5(C11K) (Ub-P5) export. PEGylation was done for 3 min at 37 °C. Organelle (PE) and supernatant (SE) fractions were processed for SDS-PAGE/Western-blot/autoradiography. The autoradiograph (upper panel) and the corresponding Ponceau S-stained membrane (lower panel) of a representative experiment (n=3) are shown. Lane I, 2% of the radiolabeled protein used in the assay. Ub-P5-PEG_n, PEGylated Ub-P5 species. Numbers to the left indicate the molecular masses of protein standards in kDa.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

Peroxisomal monoubiquitinated PEX5 interacts with the AAA ATPases PEX1 and PEX6 and is unfolded during its dislocation into the cytosol

Ana G Pedrosa, Tânia Francisco, Diana Bicho, Ana F. Dias, Aurora Barros-Barbosa, Vera Hagmann, Gabriele Dodt, Tony A Rodrigues and Jorge E. Azevedo

J. Biol. Chem. published online June 8, 2018

Access the most updated version of this article at doi: [10.1074/jbc.RA118.003669](https://doi.org/10.1074/jbc.RA118.003669)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts